Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1989-06-16
1991-12-31
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514634, 514866, A61K 31195, A61K 31155
Patent
active
050773135
ABSTRACT:
Pathological collagen cross-linking, caused in diabetes patients on account of the higher glucose concentrations, may be inhibited by means of arginine, spermidine, creatine, or agmatine, or a pharmaceutically acceptable salt thereof, in the amount of 1 to 4 g/day.
REFERENCES:
patent: 4308257 (1981-12-01), Caspe
patent: 4758583 (1988-07-01), Cerami et al.
Extra Cellular Matrixes, p. 179, in Molecular Cell Biology Ed. by Darnell et al., 1986.
"Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking", Science, vol. 232, No. 4758, Jun. 27, 1986, by M. Brownlee et al., pp. 1629-1632.
"Insulin and Glucagon Secretion in the Elederly", Chemical Abstracts, vol. 100, Mar. 26-Apr. 9, 1984, Abstract No. 97106h, by A. Pezzarossa et al.
The Merck Index, Tenth Edition, p. 113 (Arginine), p. 114, (Arginine Glutamate), p. 240 (Canavanine), p. 28 (Agmatine).
"Metabolism of L-[guanidinooxy-14C]Canavanine in the Rat", Chemical Abstracts, vol. 108, Feb. 1-Feb. 15, 1988, Abstract No. 48892t, by D. Thomas et al.
Kishore G. S.
Page Thurman K.
LandOfFree
Process for inhibiting pathological collagen cross-linking in di does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for inhibiting pathological collagen cross-linking in di, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for inhibiting pathological collagen cross-linking in di will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1510530